Am J Epidemiol 2002; 156:761-773.
Copyright © 2002 by the
Johns Hopkins Bloomberg School of Public Health
PRACTICE OF EPIDEMIOLOGY |
Empirically Calibrated Model of Hepatitis C Virus Infection in the United States
1 Global Programme on Evidence for Health Policy, World Health Organization, Geneva, Switzerland.
2 Harvard Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA.
This study presents a comprehensive epidemiologic model of hepatitis C in the United States. Through empirical calibration of model parameter values, the objectives were to gain insights into uncertain aspects of the natural history of hepatitis C and to improve the basis for projecting the future course of the epidemic. A systematic review of the published literature was conducted to define plausible ranges around model parameters, and multiple simulations of the model were undertaken using sampled values from these ranges. Model predictions produced by each set of sampled values were compared with available epidemiologic data on infection prevalence and mortality from liver cancer, and various goodness-of-fit criteria were used to identify the range of parameter values that were consistent with these data. The results of the study indicate that rates of progression to advanced liver disease may be lower than previously assumed. The authors also found that a wide range of plausible assumptions about heterogeneity in these rates, beyond that explained by age and sex, is consistent with observed epidemiologic trends. These findings have important implications both for individual clinical decisions and for broader public health policy.
carcinoma, hepatocellular; hepatitis B; hepatitis C; natural history
Abbreviations: Abbreviations: HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; NHANES III, Third National Health and Nutrition Examination Survey; SEER, Surveillance, Epidemiology, and End Results.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. M. Yeh, K. M. Kuntz, M. Ezzati, C. Hur, C. Y. Kong, and S. J. Goldie Development of an Empirically Calibrated Model of Gastric Cancer in Two High-Risk Countries Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1179 - 1187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Schackman, P. A. Teixeira, G. Weitzman, A. I. Mushlin, and I. M. Jacobson Quality-of-Life Tradeoffs for Hepatitis C Treatment: Do Patients and Providers Agree? Med Decis Making, April 1, 2008; 28(2): 233 - 242. [Abstract] [PDF]
|
|
|
|
 |
|
 J. J. Kim, K. M. Kuntz, N. K. Stout, S. Mahmud, L. L. Villa, E. L. Franco, and S. J. Goldie Multiparameter Calibration of a Natural History Model of Cervical Cancer Am. J. Epidemiol., July 15, 2007; 166(2): 137 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Goedert, B. E. Chen, L. Preiss, L. M. Aledort, P. S. Rosenberg, and for the Second Multicenter Hemophilia Cohort Study Reconstruction of the Hepatitis C Virus Epidemic in the US Hemophilia Population, 1940-1990 Am. J. Epidemiol., June 15, 2007; 165(12): 1443 - 1453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Simo, A. Lecube, J. Genesca, J. I. Esteban, and C. Hernandez Sustained Virological Response Correlates With Reduction in the Incidence of Glucose Abnormalities in Patients With Chronic Hepatitis C Virus Infection. Diabetes Care, November 1, 2006; 29(11): 2462 - 2466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Armstrong, A. Wasley, E. P. Simard, G. M. McQuillan, W. L. Kuhnert, and M. J. Alter The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 Ann Intern Med, May 16, 2006; 144(10): 705 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Lecube, C. Hernandez, J. Genesca, and R. Simo Glucose Abnormalities in Patients with Hepatitis C Virus Infection: Epidemiology and pathogenesis Diabetes Care, May 1, 2006; 29(5): 1140 - 1149. [Full Text] [PDF]
|
|
|
|
|
|
A. Lecube, C. Hernandez, J. Genesca, J. I. Esteban, R. Jardi, and R. Simo High Prevalence of Glucose Abnormalities in Patients With Hepatitis C Virus Infection: A multivariate analysis considering the liver injury Diabetes Care, May 1, 2004; 27(5): 1171 - 1175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Salomon and S. J. Goldie Cost-effectiveness of Treatment for Chronic Hepatitis C Infection--Reply JAMA, October 15, 2003; 290(15): 1994 - 1994. [Full Text] [PDF]
|
|
|
|
 |
|
 G. L Armstrong Commentary: Modelling the epidemiology of hepatitis C and its complications Int. J. Epidemiol., October 1, 2003; 32(5): 725 - 726. [Full Text] [PDF]
|
|
|
|
|
|
J. A. Salomon, M. C. Weinstein, J. K. Hammitt, and S. J. Goldie Cost-effectiveness of Treatment for Chronic Hepatitis C Infection in an Evolving Patient Population JAMA, July 9, 2003; 290(2): 228 - 237. [Abstract] [Full Text] [PDF]
|
|